Genmab (GMAB) P/S ratio

P/S ratio today
8.8×

Genmab (GMAB) trades at 8.8× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 5.2×. That is 20.1% higher than the 4.3× of fiscal 2024. Figures as of 18 Nov 2026, 07:59 UTC, from Yahoo Finance.

Key facts

P/S ratio today
8.8×
P/S ratio, fiscal 2025
5.2×
Change on fiscal 2024
+20.1%
Highest on record
13.4×fiscal 2022
Lowest on record
4.3×fiscal 2024
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Genmab P/S ratio, in more detail

Today's figure is 68.7% above the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 13.4× in fiscal 2022 and the lowest 4.3× in fiscal 2024. Today's P/S ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 7.0×.

History · 4 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Genmab P/S ratio, year by year

Genmab (GMAB) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today8.8×—$51.96—
20255.2× 20.1% up$30.80$5.93
20244.3× 50.8% down$20.87$4.83
20238.8× 34.5% down$31.84$3.63
202213.4×—$42.38$3.16
2021——$39.56—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Genmab and comparable companies
CompanyP/S ratio
Mettler-Toledo International MTD8.5×
Centene CNC0.2×
Genmab GMAB8.6×
Illumina ILMN7.1×
ResMed RMD5.9×
Zoetis ZTS3.6×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on GMAB

Genmab, figure by figure

Genmab (GMAB) overview: price, valuation and scorecardAll health care companies by market value

Genmab P/S ratio: questions and answers

What is Genmab's P/S ratio?

Genmab (GMAB) trades at 8.8× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 5.2×. That is 20.1% higher than the 4.3× of fiscal 2024.

Is Genmab's P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 7.0×.

What are the highest and lowest P/S ratio figures on record for Genmab?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 13.4× in fiscal 2022 and the lowest 4.3× in fiscal 2024.

How is Genmab's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Genmab (GMAB) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/GMAB/ps-ratio

Underlying data: Yahoo Finance.